ReviewEuropean thyroid journal2026
Iopanoic acid rapidly restores euthyroidism in refractory thyrotoxicosis pre-thyroidectomy: a retrospective study.
Review in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Restoration of euthyroidism in patients with thyrotoxicosis prior to thyroidectomy is recommended to decrease perioperative morbidity and thyroid storm risk. This is challenging when conventional anti-thyroid medication is contraindicated or ineffective. Iopanoic acid (IOPA), an iodinated contrast medium formerly used as an oral cholecystographic agent, may facilitate treatment of thyrotoxicosis, but limited manufacture precludes its use in the UK. We investigated the effectiveness and safety of IOPA for optimizing thyroid status in treatment-resistant thyrotoxicosis prior to thyroidectomy at a referral centre. Methods: With prior permission of our Drug and Therapeutics Committee, we sourced laboratory-grade (>98% pure) IOPA and administered this orally to control ongoing, severe thyrotoxicosis prior to thyroidectomy in 12 patients with inadequate response to standard therapies. Underlying aetiologies included Graves' disease, amiodarone-induced thyrotoxicosis, toxic multinodular goitre and resistance to thyroid hormone beta. Medical case notes were reviewed retrospectively to analyse clinical and biochemical outcomes. Results: All patients exhibited a decline and normalization/near-normalization of free T3 (FT3) levels (mean 55% decrease, SEM 4.5%), with minimal changes in FT4 levels. Eleven patients proceeded to uneventful thyroidectomy, and IOPA was well tolerated with no directly attributable side effects. Conclusion: IOPA is a safe and effective agent for controlling biochemical thyrotoxicosis in preparation for thyroidectomy, including disease refractory to conventional medication. Highly pure, laboratory-grade iopanoic acid that is approved for human use is now available in the UK; consideration should be given to more widespread use for emergency treatment of life-threatening hyperthyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.